In This Section      
 

Ciccarone Articles

Ciccarone Center Research

Topic

Cholesterol / Lipids / Statins

Landmark Articles

Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects.
By: Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS.
In this study of patients without baseline cognitive dysfunction, short-term data are most compatible with no adverse effect of statins on cognition, and long-term data supports a beneficial role for statins in the prevention of dementia.
Read on Pubmed
How about a worldwide effort to collaborate on developing guidelines?
By: Martin SS.
Niacin — a case study for the role of event-driven versus surrogate endpoint trials.
By: Blaha MJ, Michos ED.
Read on Pubmed
Very large database of lipids: rationale and design.
By: Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SR.
The Very Large Database of Lipids database is an ongoing protocol that harnesses de-identified data from the daily operations of a commercial lipid laboratory and provides an opportunity for collaboration and new knowledge generation through careful examination of granular lipid data on a large scale.
Read on Pubmed
Statins and cognition; a systematic review and meta-analysis of short- and long-term cognitive effects.
By: Swiger KJ, Manolac RJ, Blumenthal RS, Blaha MJ, Martin SS.

In patients without baseline cognitive dysfunction, short-term data are most compatible with no adverse effect of statins on cognition, while long-term data appear to support a beneficial role in the prevention of dementia.

Read on Pubmed
Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.
By: Chrispin J, Martin SS, Hasan RK, Joshi PH, Minder CM, McEvoy JW, Kohli P, Johnson AE, Wang L, Blaha MJ, Blumenthal RS.
Over the past 25?years, lipid-lowering therapies have been developed that are proven to not only lower cholesterol, but also to decrease adverse cardiovascular events and CVD mortality. This review highlights some key clinical trials encompassing several classes of lipid-lowering medications that have provided clinicians with an evidence-based framework for managing their patients’ cardiovascular risk.
Read on Pubmed
Statin therapy for hyperlipidemia.
By: McEvoy JW, Blumenthal RS, Blaha MJ.
Read on Pubmed
Statins for primary prevention of cardiovascular disease.
By: Minder CM, Blumenthal RS, Blaha MJ.
This article reviews the extensive evidence supporting the selective use of lipid-lowering therapy in intermediate to high-risk individuals.
Read on Pubmed
Relation of hepatic steatosis to atherogenic dyslipidemia.
By: Makadia S, Blaha MJ, Keenan T, Ndumele C, Jones S, DeFilippis A, Martin SS, Kohli P, Conceicao RD, Carvalho JA, Nasir K, Blumenthal RS, Santos R.
This article looks at the relationship between fatty liver and atherogenic lipid profiles.
Read on Pubmed
Lipid-modifying therapy.
By: Patel C, Blumenthal RS, Martin SS.
This comprehensive review goes over the evidence base for the upcoming National Cholesterol Education Program guidelines.